物流中心选址动态双钻石评价方法

以竞争优势理论中的动态双钻石模型为基础,提出物流中心选址的动态双钻石模型.该模型用区位论的要素分析方法选取区位因子,用聚类分析法设计北京市物流中心选址指标体系,用层次分析法定量解决物流中心选址问题.测算结果与北京市\     

基于聚类分析和主成分分析法的杨梅营养品质评价研究

采集温州7个地区不同东魁杨梅种植点的46个成熟杨梅样品,分析测定杨梅了10个营养参数,对所得结果进行因素聚类和主成分分析,得出了杨梅中10个营养参数之间的各自相关性,明确了影响杨梅品质的关键指标是草酸、葡萄糖和果糖组分,主成分的贡献比率分别为59.6%、23.5%和15.4%。基于糖酸比例得出了评价杨梅品质的5类品质特征。研究结果对快速评价杨梅品质优劣和指导杨梅种植具有帮助作用。      

香蕉低聚糖的通便功能评价

为比较不同品种香蕉低聚糖的通便功能,选取皇帝蕉(Musa AA Pisang Mas)和粉蕉(Musa ABB Pisang Awak),提取低聚糖后分别设置两种浓度(高剂量组2.5 g/(kg·BW·d)和低剂量组1.25 g/(kg·BW·d)),参考《保健食品检验与评价技术规范(2003版)》中\     

GA-BP神经网络及其在液体乳安全评价中的应用

利用遗传算法（Genetic Algorithm,GA）优化BP（Back Propagation,BP）神经网络的初始权值、阈值,以期加快网络收敛,提高预测精度。以乳制品中的液体乳为实验材料,建立安全评价指标体系;将优化后的GA-BP神经网络作为评价模型,对液体乳的日常检测数据进行拟合;以测试数据作为验证,检测模型的收敛速度和拟合度。结果表明GA-BP较BP神经网络来讲更稳定,能较快收敛,且仿真误差较小;在隐层节点数为9时,GA-BP神经网络对液体乳的拟合效果最好,预测精度较高,是一种可行的液体乳安全状况评价方法。      

基于电子鼻对东坡肘子加热前后特征风味变化的评价

实验利用电子鼻,结合感官评价和理化指标,采用主成分和聚类分析等统计学方法,对5种知名品牌的东坡肘子进行加热前后特征风味变化分析。结果表明:加热前,四川地区的3个样品和江南地区的2个样品表现出明显的地域性差异;加热后,两个区域的样品相似性增加,但四川地区样品的差异性扩大;进一步确认造成这种地域性差异的原因是产品配料和工艺共同所致。研究结果为东坡肘子特征风味指纹图谱的建立和标准化生产奠定基础。      

基于主成分分析法对冷冻滩羊肉品质评价模型的构建

为建立与完善冷冻滩羊肉客观评价体系,本研究分别测定经过-30、-40、-50、-60、-70℃静止空气冻结后滩羊肉的p H、汁液流失率等指标,运用主成分分析法构建滩羊肉品质的评价模型。结果表明:不同冻结温度对滩羊肉的蒸煮损失无显著影响（p>0.05）,随着冻结温度的上升,p H显著下降（p<0.05）,系水力波动降低,汁液流失率波动上升,亮度和红度值逐渐降低,剪切力值波动降低;第一至第二主成分的累积贡献率达95.74%,足以描述七项理化指标反应出的滩羊肉品质。该模型的评价结果与感官评价结果具有良好的一致性,能综合的反映滩羊肉品质的优劣,为滩羊肉理化品质的评价提供了新方法。      

考虑电动汽车响应AGC的系统网损评估

针对大规模电动汽车参与自动发电控制(automatic generation control,AGC)影响系统网损问题,提出考虑电动汽车响应AGC的系统网损评估方法。首先构建了电动汽车参与AGC框架,根据电动汽车充放电功率等信息,按系统节点估算电动汽车可用容量;然后,提出电动汽车参与AGC的网络节点功率分配方法,并建立考虑电动汽车参与AGC的系统网损评估模型,进行系统网损评估;最后,以IEEE-118节点系统为例进行仿真分析,结果表明,与发电机组参与AGC相比,电动汽车参与AGC,无风电接入时更有利于系统网损维持在一定水平,有风电接入时对系统网损水平影响更大。     

反渗透专用阻垢剂性能的动态评价方法

综述了近年来反渗透专用阻垢剂的动态评价方法,包括给水一次通过法、全循环法、部分循环法、间歇循环法。从运行过程中溶液浓度的变化、化学药品的消耗量、模拟停留时间、结垢的种类等几方面对这4种评价方法进行了分析和比较,总结了各种方法的优缺点和适用范围,为人们选择和开发合适的阻垢剂评价方法提供了可靠的依据。     

高阻尼混凝土的耐久性试验与综合评定

在水泥砂浆中掺加一定掺量的苯丙乳液、聚醋酸乙烯乳液、甲基纤维素、乳胶和硅粉,可以提高聚合物阻尼增强水泥砂浆的损耗因子和储存模量,为了研究这些掺料对混凝土长期性能的影响,采用能分别体现高阻尼混凝土抗冻融能力、抗氯离子渗透能力和抗渗能力的4个指标(即剥落量、耐冻融系数、通过电量和渗水深度)作为影响因素,在试验的基础上,应用模糊综合评定的方法评定了高阻尼混凝土的耐久性,为今后混凝土耐久性的综合评估提供了一种新的探索.     

Development of a Multi-Epitope Vaccine for Mycoplasma hyopneumoniae and Evaluation of Its Immune Responses in Mice and Piglets

Mycoplasma hyopneumoniae (Mhp), the primary pathogen causing Mycoplasma pneumonia of swine (MPS), brings massive economic losses worldwide. Genomic variability and post-translational protein modification can enhance the immune evasion of Mhp, which makes MPS prone to recurrent outbreaks on farms, even with vaccination or other treatments. The reverse vaccinology pipeline has been developed as an attractive potential method for vaccine development due to its high efficiency and applicability. In this study, a multi-epitope vaccine for Mhp was developed, and its immune responses were evaluated in mice and piglets. Genomic core proteins of Mhp were retrieved through pan-genome analysis, and four immunodominant antigens were screened by host homologous protein removal, membrane protein screening, and virulence factor identification. One immunodominant antigen, {"type":"entrez-protein","attrs":{"text":"AAV27984.1","term_id":"53987783","term_text":"AAV27984.1"}}AAV27984.1 (membrane nuclease), was expressed by E. coli and named rMhp597. For epitope prioritization, 35 B-cell-derived epitopes were identified from the four immunodominant antigens, and 10 MHC-I and 6 MHC-II binding epitopes were further identified. The MHC-I/II binding epitopes were merged and combined to produce recombinant proteins MhpMEV and MhpMEVC6His, which were used for animal immunization and structural analysis, respectively. Immunization of mice and piglets demonstrated that MhpMEV could induce humoral and cellular immune responses. The mouse serum antibodies could detect all 11 synthetic epitopes, and the piglet antiserum suppressed the nuclease activity of rMhp597. Moreover, piglet serum antibodies could also detect cultured Mhp strain 168. In summary, this study provides immunoassay results for a multi-epitope vaccine derived from the reverse vaccinology pipeline, and offers an alternative vaccine for MPS.